Firms

Founded

—

Type

Venture capital

Team

No team members on record yet.

Co-investing

ARCH Venture Partners

• Xaira Therapeutics$1B · 2024-04-01
• Remix Therapeutics$81M · 2020-12-08
• Bit Bio$41M · 2020-06-14
• Lyell Immunopharma$493M · 2020
• Lyell Immunopharma$179M · 2019

Bain Capital

• Solid Biosciences$50M · 2017
• Replimune$55M · Unknown date
• Nurix$120M · Unknown date
• Replimune Group$55M · Unknown date
• Nurix Therapeutics$120M · Unknown date

Atlas Venture

• Remix Therapeutics$81M · 2020-12-08
• Replimune$55M · Unknown date
• Replimune Group$55M · Unknown date

Cormorant Asset Management

• Solid Biosciences$50M · 2017
• Replimune$55M · Unknown date
• Replimune Group$55M · Unknown date

Forbion

• Engrail Therapeutics$167M · 2024-03-19
• Replimune$55M · Unknown date
• Replimune Group$55M · Unknown date

SHOW MORE

Investments

$1B2024-04-01	Xaira Therapeutics	ARCH Venture Partners, Primary Venture Partners, Foresite Capital
$167M2024-03-19	Engrail Therapeutics	Norwest Venture Partners, F-Prime Capital, Forbion, Longwood Fund, RiverVest Venture Partners, Red Tree Venture Capital, Ysios Capital, Eight Roads, Pivotal Life Sciences, Foresite Capital
$23M2022-06-21	MyOme, Inc.	Founders Fund, Sequoia Capital, SoftBank Group Corp., Foresite Capital, Sequoia
$274M2022	Pardes Biosciences	Y Combinator, Foresite Capital
$81M2020-12-08	Remix Therapeutics	ARCH Venture Partners, Atlas Venture, Alexandria Venture Investments, Foresite Capital, The Column Group
$41M2020-06-14	Bit Bio	ARCH Venture Partners, BlueYard Capital, Foresite Capital
$493M2020	Lyell Immunopharma	ARCH Venture Partners, Foresite Capital
$179M2019	Lyell Immunopharma	ARCH Venture Partners, Foresite Capital
$50M2017	Solid Biosciences	Bain Capital, Perceptive Advisors, Foresite Capital, RA Capital Management, Cormorant Asset Management
$55MUnknown date	Replimune	Bain Capital, Atlas Venture, Foresite Capital, Cormorant Asset Management, Omega Funds, Forbion

SHOW MORE